While chances of her leaked plan to force lower drug prices in the United States getting through the Republican-controlled Senate are extremely small, House Speaker Nancy Pelosi, D-California, put biosimilars, including insulins, into the national conversation this week.
While chances of her leaked plan to force lower drug prices in the United States getting through the Republican-controlled Senate are extremely small, House Speaker Nancy Pelosi, D-California, put biosimilars, including insulins, into the national conversation this week.
The leaked plan proposes that the secretary of HHS should have the power to “to directly negotiate prices on the top 250 drugs with the greatest total cost to Medicare and the entire US health system without competition from at least [2] generic, biosimilar or interchangeable biologics on the market.”
Each year, the most expensive 250 drugs would be subject to review. Not only that, but the price would be available to all payers—not just Medicare, the document says.
The top 5 drug products with the highest total spending in 2016 accounted for approximately 10% of total prescription drug spending among large employer plans, Medicare Part D, and Medicaid. Among large employers, Humira ($4.9 billion) and Enbrel ($2.4 billion), both of which have FDA-approved but unlaunched biosimilar options, were responsible for the greatest share of spending.
The issue of drug pricing promises to continue over the next year, since, while numerous proposals have been issued by Republicans and Democrats alike, none have gained any momentum, given staunch industry opposition and a divided Washington.
Borrowing a bit from President Donald Trump’s International Pricing Index (IPI) proposal plan, the Pelosi plan would set an upper limit for the price reached in any negotiation as no more than 1.2 times, or 120% of, the volume-weighted average of price of 6 countries (Australia, Canada, France, Germany, Japan, and the United Kingdom).
Writing in The Federalist, Christopher Jacobs called that part of the plan “the de facto imposition of price controls.”
The plan comes with stiff, retroactive penalties for pharmaceutical firms that refuse to comply:
In addition, all 8000 drugs in Medicare Part B and D would have a new inflation rebate to deter price hikes. If a pharmaceutical company has raised the price of a drug in Part B or D above the rate of inflation since 2016, they can either lower the price or be required to pay the entire price above inflation in a rebate back to the government.
A report released by CMS last year found that Medicare and its beneficiaries spend $8.1 billion more on drugs than they would if payments were scaled by international price ratios.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.